T1	PROC 47 102	Estudio de fase 3b/4 aleatorizado, abierto, enmascarado
T2	PROC 145 192	comparar la seguridad y la eficacia enmascarada
T3	LIVB 202 213	evaluadores
T4	CHEM 217 229	upadacitinib
T5	CHEM 239 248	dupilumab
#1	AnnotatorNotes T5	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	LIVB 252 261	pacientes
#2	AnnotatorNotes T6	C0030705; Patients; Patient or Disabled Group
T7	DISO 266 284	dermatitis atópica
#3	AnnotatorNotes T7	C0011615; Dermatitis, Atopic; Disease or Syndrome
T8	DISO 327 345	Dermatitis atópica
#4	AnnotatorNotes T8	C0011615; Dermatitis, Atopic; Disease or Syndrome
T9	DISO 367 373	Eczema
#5	AnnotatorNotes T9	C0013595; Eczema; Disease or Syndrome
T10	LIVB 403 412	Pacientes
#6	AnnotatorNotes T10	C0030705; Patients; Patient or Disabled Group
T11	Age 413 421	≥12 años
T12	Age 455 463	<65 años
T13	LIVB 468 475	Sujetos
#7	AnnotatorNotes T13	C0681850; Study Subject; Group
T14	DISO 480 490	DA crónica
T15	Duration 483 490	crónica
T16	DISO 497 505	síntomas
#8	AnnotatorNotes T16	C1457887; Symptoms; Sign or Symptom
T17	Duration 518 533	al menos 3 años
T18	ANAT 654 673	superficie corporal
T19	ANAT 675 677	SC
#9	AnnotatorNotes T19	C0456944; Coronary sinus structure; Body Part, Organ, or Organ Component | C1269893; Entire coronary sinus; Body Part, Organ, or Organ Component
T20	DISO 695 697	DA
T21	PROC 710 716	visita
T22	Frequency 736 743	semanal
T23	Frequency 767 773	diaria
T24	PROC 780 786	WP-NRS
T25	PROC 849 870	tratamiento sistémico
T26	PROC 967 988	tratamiento sistémico
T27	DISO 1004 1006	DA
T28	PROC 1070 1093	tratamientos sistémicos
T29	Contraindicated 1070 1093	tratamientos sistémicos
T30	CHEM 1179 1195	inhibidor de JAK
T31	Route 1196 1200	oral
T32	Route 1203 1209	tópico
T33	CHEM 1235 1247	upadacitinib
T34	CHEM 1249 1255	Rinvoq
T35	CHEM 1259 1270	tofacitinib
#10	AnnotatorNotes T35	C2930696; tofacitinib; Organic Chemical · Pharmacologic Substance
T36	CHEM 1272 1279	Xeljanz
T37	CHEM 1283 1294	ruxolitinib
#11	AnnotatorNotes T37	C2931926; ruxolitinib; Organic Chemical · Pharmacologic Substance
T38	CHEM 1296 1302	Jakafi
#12	AnnotatorNotes T38	C3247913; Jakafi; Organic Chemical · Pharmacologic Substance
T39	CHEM 1306 1314	Opzelura
T40	CHEM 1318 1329	baricitinib
#13	AnnotatorNotes T40	C4044947; baricitinib; Organic Chemical · Pharmacologic Substance
T41	CHEM 1331 1339	Olumiant
T42	CHEM 1343 1354	peficitinib
T43	CHEM 1356 1362	Smyraf
T44	CHEM 1366 1377	abrocitinib
T45	CHEM 1379 1386	Cibinqo
T46	CHEM 1391 1401	filgotinib
#14	AnnotatorNotes T46	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T47	CHEM 1403 1411	Jyseleca
T48	CHEM 1437 1446	dupilumab
#15	AnnotatorNotes T48	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T49	CHEM 1448 1460	tralokinumab
T50	CHEM 1463 1475	lebrikizumab
T51	LIVB 112 123	evaluadores
T52	PROC 576 604	criterios de Hanifin y Rajka
T53	PROC 620 624	EASI
T54	Route 979 988	sistémico
T55	Route 861 870	sistémico
T56	Route 1083 1093	sistémicos
T57	Quantifier_or_Qualifier 285 301	moderada o grave
T58	Quantifier_or_Qualifier 349 365	moderada a grave
T59	Result_or_Value 425 431	≥40 kg
T60	CONC 438 451	momento basal
T61	CONC 544 557	momento basal
T62	CONC 620 624	EASI
T63	Result_or_Value 625 628	≥16
T64	CONC 641 648	vIGA-AD
T65	Result_or_Value 649 651	≥3
T66	Result_or_Value 698 703	≥10 %
T67	Quantifier_or_Qualifier 717 722	basal
T68	Quantifier_or_Qualifier 744 749	basal
T69	Result_or_Value 787 789	≥4
T70	Observation 823 845	respuesta insuficiente
T71	Observation 923 945	respuesta insuficiente
T72	Quantifier_or_Qualifier 955 966	al menos un
T73	Patient 252 261	pacientes
T74	Patient 403 412	Pacientes
T75	Patient 468 475	Sujetos
T76	History_of 849 870	tratamiento sistémico
T77	History_of 967 988	tratamiento sistémico
T78	History_of 1179 1195	inhibidor de JAK
T79	History_of 1235 1247	upadacitinib
T80	History_of 1249 1255	Rinvoq
T81	History_of 1259 1270	tofacitinib
T82	History_of 1272 1279	Xeljanz
T83	History_of 1283 1294	ruxolitinib
T84	History_of 1296 1302	Jakafi
T85	History_of 1306 1314	Opzelura
T86	History_of 1318 1329	baricitinib
T87	History_of 1331 1339	Olumiant
T88	History_of 1343 1354	peficitinib
T89	History_of 1356 1362	Smyraf
T90	History_of 1366 1377	abrocitinib
T91	History_of 1379 1386	Cibinqo
T92	History_of 1391 1401	filgotinib
T93	History_of 1403 1411	Jyseleca
T94	History_of 1437 1446	dupilumab
T95	History_of 1448 1460	tralokinumab
T96	History_of 1463 1475	lebrikizumab
T97	History_of 823 845	respuesta insuficiente
T98	History_of 923 945	respuesta insuficiente
